Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) Operating Income

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) (EUCRU) currently reports a operating income of $-700K as of December 2022. That compares with $-1M in the prior-year period — up 30.3% year over year. Use the charts on this page to explore Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s operating income history and peer comparisons.

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War)'s operating income increased from $-1M to $-700K — a 30.3% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War) reported $-700K in operating income as of December 2022. That compares with $-1M in the prior-year period — up 30.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-700K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eucrates Biomedical Acquisition - Units (1 Ord & 1/3 War), and consider following EUCRU for alerts when major investors trade the stock.